• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Biote Reports First Quarter 2025 Financial Results

    5/7/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email

    Strong financial performance driven in part by increased gross margin from vertical integration

    Announces organizational restructuring to drive sustainable growth and build long-term value

    Maintains 2025 financial outlook

    First Quarter 2025 Financial Highlights

    • Revenue of $49.0 million
    • Gross profit margin of 74.3%
    • Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period
    • Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1%

    Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2025.

    "Biote's first quarter results benefited from efficiencies related to the vertical integration of our 503B manufacturing facility as well as growth in our dietary supplements business," said Bret Christensen, Biote Chief Executive Officer. "Total first quarter revenue increased 4.7% year-over-year, primarily due to a 25.5% increase in dietary supplements revenue. Procedure revenue decreased 3.6% year-over-year, reflecting reduced commercial effectiveness and a slowdown in new clinic additions. We are focused on driving new clinic growth throughout our network."

    Mr. Christensen continued, "Last year, Biote embarked on an ambitious plan designed to strengthen our competitive moat and broaden our capabilities to better serve the growing market for hormone optimization and therapeutic wellness. Among our key accomplishments were the phased launch of BioteRx, the vertical integration of our 503B manufacturing facility and the introduction of targeted enhancements to our proprietary clinical decision support software.

    "Having expanded our capabilities and product offerings, Biote today is announcing a strategic organizational restructuring designed to drive sustainable growth and create long-term value for stakeholders. The decisive actions we are taking aim to significantly increase new provider wins, maximize value from our existing top-tier providers, and improve our financial performance by enhancing our operational accountability and discipline. I believe that these initiatives, coupled with our focus on optimizing sales and marketing strategy, will strengthen our commercial organization through increased productivity."

    2025 First Quarter Financial Review

    (All financial result comparisons made are against the prior-year period unless otherwise noted)

    Total revenue was $49.0 million, representing an increase of 4.7% from $46.8 million. Procedure revenue decreased 3.6% and dietary supplement revenue increased 25.5%.

    Gross profit margin was 74.3% compared to 71.3% for the first quarter of 2024. The increase in gross profit margin was primarily due to the vertical integration of our 503B manufacturing facility and effective cost management.

    Operating income was $9.7 million, compared to $10.4 million. Operating income in the first quarter of 2025 decreased as higher gross profit was more than offset by increased sales and marketing activities to reaccelerate new customer growth and increased professional services.

    Net income was $15.8 million and diluted earnings per share attributable to biote Corp. stockholders was $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12). Net income for the first quarter of 2025 included a gain of $10.7 million, while net loss for the first quarter of 2024 included a loss of $(12.1) million due to changes in the fair value of the earnout liabilities for the respective periods.

    Adjusted EBITDA for the first quarter of 2025 was $13.8 million, with an Adjusted EBITDA margin of 28.1%. This compares to first quarter 2024 Adjusted EBITDA of $14.2 million, with an Adjusted EBITDA margin of 30.4%. Although Adjusted EBITDA exceeded our expectations for the first quarter of 2025, both Adjusted EBITDA and Adjusted EBITDA margin decreased compared to the prior-year period primarily due to increased sales and marketing activities to reaccelerate new customer growth.

    Subsequent Event

    Today Biote announced an organizational restructuring of the Company's commercial teams to support Biote's newly expanded capabilities and drive improved operational and financial performance. The Company's restructuring actions seek to prioritize new clinic growth, maximize value from existing top-tier providers and strengthen accountability and discipline throughout the organization.

    We are taking the following actions:

    • Realigning our commercial organization and directing all resources to drive revenue growth
    • Consistent with our strategy, we are strengthening sales force productivity by transitioning certain commercial support personnel to active field sales roles, effectively increasing sales representatives by 25% without hiring new personnel
    • Streamlining our sales leadership to enhance sales efficiency and drive more consistent performance across the entire commercial team
    • Directly aligning our sales compensation with internal sales goals
    • Extending our leadership position by enhancing our compelling value proposition to providers and patients

    The Company expects to incur a charge of approximately $0.6 million to $0.8 million related to severance costs in the second quarter of 2025 due to this restructuring.

    2025 Financial Outlook

    Mr. Christensen concluded, "Biote remains on track to meet our financial guidance for fiscal 2025. The strategic reorganization we are undertaking represents an important next step in Biote's evolution as we continue our mission to transform healthy aging and become the preferred single-source provider of evidence-based therapeutic wellness solutions."

    ($ in millions)

    2025 Guidance Ranges

    Revenue

    $202-$208

    Adjusted EBITDA2

    $59-$64

    • 2025 Procedure revenue is expected to increase approximately 2-4% from 2024.
    • 2025 Dietary supplements revenue is expected to increase approximately 5-10% from 2024.

    For the second quarter of 2025, the Company expects revenue and Adjusted EBITDA to be similar to or slightly higher than that of the second quarter of 2024.

    Conference Call:

    Biote management will host a conference call to review these results and provide a business update beginning at 5:00 p.m. ET on Wednesday, May 7, 2025. To access the conference call by telephone, please dial (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). To access a live webcast of the call, interested parties may use the following link: Biote First Quarter 2025 Earnings Conference Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, at ir.biote.com, shortly after the event concludes.

    Discussion of Non-GAAP Financial Measures

    To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a non-GAAP financial measure that it calculates as net income before interest, taxes and depreciation and amortization, further adjusted to exclude stock-based compensation, litigation expenses, legal settlements, transaction-related expenses, merger and acquisition expenses, fair value adjustments to certain equity instruments classified as liabilities and other expenses. Below we have provided a reconciliation of Adjusted EBITDA to net income, the most directly comparable GAAP financial measure.

    We present Adjusted EBITDA and Adjusted EBITDA margin because it is a key measure used by our management to evaluate our operating performance, generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA and Adjusted EBITDA margin provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management.

    Adjusted EBITDA and Adjusted EBITDA margin have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:

    • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA and Adjusted EBITDA margin do not reflect cash capital expenditure requirements for such replacements of our assets;
    • Adjusted EBITDA and Adjusted EBITDA margin do not reflect changes in, or cash requirements for, our working capital needs; and
    • Adjusted EBITDA and Adjusted EBITDA margin do not reflect tax payments that may represent a reduction in cash available to us.

    In addition, Adjusted EBITDA and Adjusted EBITDA margin are subject to inherent limitations as it reflects the exercise of judgment by Biote's management about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA and Adjusted EBITDA margin alongside other financial performance measures, including net income and our other GAAP results.

    Forward-Looking Non-GAAP Financial Measures

    The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of certain information needed to calculate reconciling items. For example, the Company has not included a reconciliation of projected Adjusted EBITDA to GAAP net income (loss), which is the most directly comparable GAAP measure, for the periods presented in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. The Company's projected Adjusted EBITDA excludes certain items that are inherently uncertain and difficult to predict including, but not limited to, share-based compensation expense, income taxes, due diligence expenses and legal expenses. Due to the variability, complexity and limited visibility of the adjusting items that would be excluded from projected Adjusted EBITDA in future periods, management does not forecast them for internal use and therefore cannot create a quantitative projected Adjusted EBITDA to GAAP net income (loss) reconciliation for the periods presented without unreasonable efforts. A quantitative reconciliation of projected Adjusted EBITDA to GAAP net income (loss) for the periods presented would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors. From a qualitative perspective, it is anticipated that the differences between projected Adjusted EBITDA to GAAP net income (loss) for the periods presented will consist of items similar to those described in the financial tables later in this release, including, for example and without limitation, share-based compensation expense, income taxes, due diligence expenses and legal expenses. The timing and amount of any of these excluded items could significantly impact the Company's GAAP net income (loss) for a particular period. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis.

    About Biote

    Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

    _____________________________

    1Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. Please see "Discussion of non-GAAP Financial Measures" for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measure.

    2 Please see "Forward-Looking Non-GAAP Financial Measures" below for additional information about forward-looking Adjusted EBITDA.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words "may," "can," "should," "will," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "hope," "believe," "seek," "target," "continue," "could," "might," "ongoing," "potential," "predict," "would" and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers' reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers' sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the "Risk Factors" section of the Biote's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the "SEC") on March 14, 2025, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

    Financial Tables

    Biote Corp.

    Condensed Consolidated Balance Sheets (In Thousands) (Unaudited)

     

     

     

    March 31,

     

    December 31,

     

     

    2025

     

    2024

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    41,700

     

     

    $

    39,342

     

    Accounts receivable, net

     

     

    7,765

     

     

     

    7,631

     

    Inventory, net

     

     

    13,451

     

     

     

    14,845

     

    Other current assets

     

     

    5,764

     

     

     

    6,309

     

    Total current assets

     

     

    68,680

     

     

     

    68,127

     

    Property and equipment, net

     

     

    8,389

     

     

     

    6,973

     

    Capitalized software, net

     

     

    3,760

     

     

     

    3,877

     

    Goodwill

     

     

    5,833

     

     

     

    5,833

     

    Intangible assets, net

     

     

    5,192

     

     

     

    5,500

     

    Operating lease right-of-use assets

     

     

    3,113

     

     

     

    3,246

     

    Deferred tax assets, net

     

     

    28,340

     

     

     

    28,742

     

    Other non-current assets

     

     

    72

     

     

     

    72

     

    Total assets

     

    $

    123,379

     

     

    $

    122,370

     

     

     

     

     

     

    Liabilities and Stockholders' Deficit

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable

     

    $

    3,335

     

     

    $

    5,813

     

    Accrued expenses

     

     

    10,228

     

     

     

    11,293

     

    Term loan, current

     

     

    6,250

     

     

     

    6,250

     

    Deferred revenue, current

     

     

    3,036

     

     

     

    2,961

     

    Earnout liabilities, current

     

     

    —

     

     

     

    100

     

    Operating lease liabilities, current

     

     

    540

     

     

     

    523

     

    Share repurchase liabilities, current

     

     

    25,081

     

     

     

    24,574

     

    Total current liabilities

     

     

    48,470

     

     

     

    51,514

     

    Term loan, net of current portion

     

     

    99,847

     

     

     

    101,199

     

    Deferred revenue, net of current portion

     

     

    1,450

     

     

     

    1,553

     

    Operating lease liabilities, net of current portion

     

     

    2,747

     

     

     

    2,890

     

    Share repurchase liabilities, net of current portion

     

     

    44,858

     

     

     

    44,300

     

    Other non-current liability

     

     

    —

     

     

     

    1,500

     

    TRA liability

     

     

    4,386

     

     

     

    4,479

     

    Earnout liabilities, net of current portion

     

     

    6,447

     

     

     

    17,135

     

    Total liabilities

     

     

    208,205

     

     

     

    224,570

     

    Commitments and contingencies

     

     

     

     

    Stockholders' Deficit

     

     

     

     

    Preferred stock

     

     

    —

     

     

     

    —

     

    Class A common stock

     

     

    3

     

     

     

    3

     

    Class V voting stock

     

     

    1

     

     

     

    1

     

    Additional paid-in capital

     

     

    —

     

     

     

    —

     

    Accumulated deficit

     

     

    (84,346

    )

     

     

    (100,297

    )

    Accumulated other comprehensive loss

     

     

    (39

    )

     

     

    (35

    )

    Treasury stock, at cost

     

     

    (5,600

    )

     

     

    (5,600

    )

    biote Corp.'s stockholders' deficit

     

     

    (89,981

    )

     

     

    (105,928

    )

    Noncontrolling interest

     

     

    5,155

     

     

     

    3,728

     

    Total stockholders' deficit

     

     

    (84,826

    )

     

     

    (102,200

    )

    Total liabilities and stockholders' deficit

     

    $

    123,379

     

     

    $

    122,370

     

    Biote Corp.

    Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (In Thousands, except share and per share amounts) (Unaudited)

     

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

    Revenue:

     

     

     

     

    Product revenue

     

    $

    47,025

     

     

    $

    46,035

     

    Service revenue

     

     

    1,967

     

     

     

    769

     

    Total revenue

     

     

    48,992

     

     

     

    46,804

     

    Cost of revenue

     

     

     

     

    Cost of products

     

     

    11,654

     

     

     

    12,887

     

    Cost of services

     

     

    956

     

     

     

    565

     

    Cost of revenue

     

     

    12,610

     

     

     

    13,452

     

    Selling, general and administrative

     

     

    26,692

     

     

     

    22,925

     

    Income from operations

     

     

    9,690

     

     

     

    10,427

     

    Other income (expense), net:

     

     

     

     

    Interest expense, net

     

     

    (2,905

    )

     

     

    (1,660

    )

    Gain (loss) from change in fair value of earnout liabilities

     

     

    10,688

     

     

     

    (12,089

    )

    Other expense

     

     

    (18

    )

     

     

    (2

    )

    Total other income (expense), net

     

     

    7,765

     

     

     

    (13,751

    )

    Income (loss) before provision for income taxes

     

     

    17,455

     

     

     

    (3,324

    )

    Income tax expense

     

     

    1,616

     

     

     

    2,402

     

    Net income (loss)

     

     

    15,839

     

     

     

    (5,726

    )

    Less: Net income (loss) attributable to noncontrolling interest

     

     

    2,121

     

     

     

    (1,565

    )

    Net income (loss) attributable to biote Corp. stockholders

     

    $

    13,718

     

     

    $

    (4,161

    )

     

     

     

     

     

    Other comprehensive loss:

     

     

     

     

    Foreign currency translation adjustments

     

     

    (4

    )

     

     

    (1

    )

    Other comprehensive loss

     

     

    (4

    )

     

     

    (1

    )

    Comprehensive income (loss)

     

    $

    15,835

     

     

    $

    (5,727

    )

     

     

     

     

     

    Net income per common share

     

     

     

     

    Basic

     

    $

    0.44

     

     

    $

    (0.12

    )

    Diluted

     

    $

    0.37

     

     

    $

    (0.12

    )

    Weighted average common shares outstanding

     

     

     

     

    Basic

     

     

    31,485,777

     

     

     

    34,621,166

     

    Diluted

     

     

    36,952,961

     

     

     

    34,621,166

     

    Biote Corp.

    Condensed Consolidated Statements of Cash Flows (In Thousands) (Unaudited)

     

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

    Operating Activities

     

     

     

     

    Net income (loss)

     

    $

    15,839

     

     

    $

    (5,726

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities:

     

     

     

     

    Depreciation and amortization

     

     

    857

     

     

     

    750

     

    Bad debt expense

     

     

    773

     

     

     

    161

     

    Amortization of debt issuance costs

     

     

    211

     

     

     

    202

     

    Provision for obsolete inventory

     

     

    442

     

     

     

    70

     

    Non-cash lease expense

     

     

    133

     

     

     

    80

     

    Non-cash interest on share repurchase liability

     

     

    1,065

     

     

     

    —

     

    Share-based compensation expense

     

     

    2,127

     

     

     

    1,763

     

    (Gain) loss from change in fair value of earnout liabilities

     

     

    (10,688

    )

     

     

    12,089

     

    Deferred income taxes

     

     

    508

     

     

     

    —

     

    Changes in operating assets and liabilities:

     

     

     

     

    Accounts receivable

     

     

    (907

    )

     

     

    (1,329

    )

    Inventory

     

     

    952

     

     

     

    75

     

    Other assets

     

     

    545

     

     

     

    619

     

    Accounts payable

     

     

    (2,478

    )

     

     

    (109

    )

    Deferred revenue

     

     

    (28

    )

     

     

    (22

    )

    Accrued expenses

     

     

    (2,665

    )

     

     

    (1,178

    )

    Payments pursuant to TRA

     

     

    (93

    )

     

     

    —

     

    Operating lease liabilities

     

     

    (126

    )

     

     

    (73

    )

    Net cash provided by operating activities

     

     

    6,467

     

     

     

    7,372

     

    Investing Activities

     

     

     

     

    Purchases of property and equipment

     

     

    (1,630

    )

     

     

    (704

    )

    Purchases of capitalized software

     

     

    (218

    )

     

     

    (350

    )

    Acquisitions, net of cash acquired

     

     

    —

     

     

     

    (11,122

    )

    Net cash used in investing activities

     

     

    (1,848

    )

     

     

    (12,176

    )

    Financing Activities

     

     

     

     

    Repurchases of common stock

     

     

    —

     

     

     

    (4,088

    )

    Principal repayments on term loan

     

     

    (1,563

    )

     

     

    (1,562

    )

    Proceeds from exercise of stock options

     

     

    —

     

     

     

    324

     

    Distributions

     

     

    (694

    )

     

     

    (83

    )

    Net cash used in financing activities

     

     

    (2,257

    )

     

     

    (5,409

    )

    Effect of exchange rate changes on cash and cash equivalents

     

     

    (4

    )

     

     

    (2

    )

    Net increase (decrease) in cash and cash equivalents

     

     

    2,358

     

     

     

    (10,215

    )

    Cash and cash equivalents at beginning of period

     

     

    39,342

     

     

     

    89,002

     

    Cash and cash equivalents at end of period

     

    $

    41,700

     

     

    $

    78,787

     

    Supplemental Disclosure of Cash Flow Information

     

     

     

     

    Cash paid for interest

     

    $

    2,016

     

     

    $

    2,230

     

    Cash paid for income taxes

     

    $

    2

     

     

    $

    2

     

    Non-cash investing and financing activities

     

     

     

     

    Capital expenditures and capitalized software included in accounts payable

     

    $

    —

     

     

    $

    85

     

    Shares issued to acquire Simpatra

     

    $

    —

     

     

    $

    1,574

     

    Biote Corp.

    Reconciliation of Adjusted EBITDA to Net Income (Loss) (Unaudited)

       

    The following table presents a reconciliation of net income (loss) to Adjusted EBITDA, as well as the calculation of net income (loss) margin and Adjusted EBITDA margin, for each of the periods indicated.

     

     

     

    Three Months Ended

     

     

    March 31,

    (in thousands)

     

    2025

     

    2024

    Net income (loss)

     

    $

    15,839

     

     

    $

    (5,726

    )

    Interest expense, net(1)

     

     

    2,905

     

     

     

    1,660

     

    Income tax expense

     

     

    1,616

     

     

     

    2,486

     

    Depreciation and amortization(2)

     

     

    857

     

     

     

    750

     

    Share-based compensation expense(3)

    `

     

    2,127

     

     

     

    1,763

     

    Litigation expenses-former owner(4)

     

     

    150

     

     

     

    601

     

    Litigation-other(5)

     

     

    465

     

     

     

    70

     

    Legal settlement and related expenses(6)

     

     

    36

     

     

     

    —

     

    Transaction-related expenses(7)

     

     

    —

     

     

     

    45

     

    Other expenses(8)

     

     

    335

     

     

     

    85

     

    Merger and acquisition expenses(9)

     

     

    110

     

     

     

    419

     

    (Gain) loss from change in fair value of earnout liabilities

     

     

    (10,688

    )

     

     

    12,089

     

    Adjusted EBITDA

     

    $

    13,752

     

     

    $

    14,242

     

    Total revenue

     

    $

    48,992

     

     

    $

    46,804

     

    Net income (loss) margin(10)

     

     

    32.3

    %

     

     

    -12.2

    %

    Adjusted EBITDA margin(11)

     

     

    28.1

    %

     

     

    30.4

    %

    (1)

    Represents cash and non-cash interest on our debt obligations, commitment fees for our unused Revolving Loans, net of interest income earned on our money market account and short-term investment. For the three months ended March 31, 2025, interest expense, net included $1.1 million of accreted interest related to the share repurchase liability. There was no accreted interest for the three months ended March 31, 2024.

     

    (2)

    Represents depreciation expense on property and equipment, amortization expense on capitalized software and amortization expense on purchased intangible assets. Depreciation expense of $0.01 million was included in cost of products for the three months ended March 31, 2025. There was no depreciation expense included in cost of products for the three months ended March 31, 2024.

     

    (3)

    Represents employee compensation expense associated with equity-based stock awards. This includes expense associated with equity incentive instruments including phantom stock awards, stock options and restricted stock units.

     

    (4)

    Represents legal expenses to defend the Company against claims asserted by the Company's former owner.

     

    (5)

    Represents litigation expenses other than those incurred in connection with claims asserted by the Company's former owner that are not related to the Company's ongoing business.

     

    (6)

    Represents legal expenses incurred in connection with litigation settlement gains or losses.

     

    (7)

    Represents transaction costs including legal fees of $0.04 million during the three months ended March 31, 2024, which were incurred in connection with the filing of, and transactions contemplated by, the Company's securities offerings. No such filing fees were incurred during the three months ended March 31, 2025.

     

    (8)

    Represents strategic consulting and legal expenses related to the recent CEO transition of $0.3 million and a realized foreign currency loss of less than $0.01 million for the three months ended March 31, 2025. Represents executive severance costs of $0.08 million and a realized foreign currency loss of less than $0.01 million for the three months ended March 31, 2024.

     

    (9)

    Represents legal fees and professional fees totaling $0.01 million incurred during the three months ended March 31, 2025 to finalize the purchase price allocation of Asteria Health and for other strategic opportunities to expand the business. Represents legal fees of $0.4 million and professional services fees of $0.1 million incurred during the three months ended March 31, 2024 related to our 2024 acquisitions.

     

    (10)

    Net income (loss) margin is defined as net income (loss) divided by total revenue.

     

    (11)

    Adjusted EBITDA margin is defined as adjusted EBITDA divided by total revenue.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507023704/en/

    Investor Relations:

    Eric Prouty

    AdvisIRy Partners

    [email protected]

    Media:

    [email protected]

    Get the next $BTMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on biote Corp.

      Craig Hallum initiated coverage of biote Corp. with a rating of Buy

      12/16/24 8:50:55 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • B. Riley Securities initiated coverage on biote Corp. with a new price target

      B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

      2/20/24 6:47:29 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on biote Corp.

      Jefferies initiated coverage of biote Corp. with a rating of Buy

      2/1/24 6:18:15 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Barrera Richard R

      4 - biote Corp. (0001819253) (Issuer)

      6/11/25 6:54:32 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Morris Debra L converted options into 11,045 shares, increasing direct ownership by 28% to 50,155 units (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/15/25 11:26:51 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Heyer Steven J

      4 - biote Corp. (0001819253) (Issuer)

      5/14/25 7:42:41 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biote Names Rich Barrera to Board of Directors

      biote Corp.(NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. "We are pleased to welcome Rich Barrera to Biote's Board of Directors," said Marc Beer, Executive Chairman of Biote. "Rich has a distinguished background as an investment professional, founding Roystone Capital in 2012 and managing investment portfolios for more than 20 years. For the past few years, we've had the pleasure of working with Rich and his team at Roystone, which is one of Biote's top institutional shareholders

      6/9/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    SEC Filings

    See more
    • Biote Corp. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - biote Corp. (0001819253) (Filer)

      6/9/25 4:40:16 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Biote Corp.

      8-K - biote Corp. (0001819253) (Filer)

      6/5/25 8:22:07 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Biote Corp.

      8-K - biote Corp. (0001819253) (Filer)

      5/14/25 4:15:31 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Biote to Purchase Asteria Health

      Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

      1/17/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Names Robert Peterson as Chief Financial Officer

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

      1/11/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Financials

    Live finance-specific insights

    See more
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Fourth Quarter and Full Year 2024 Financial Results

      Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to

      3/12/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biote Corp.

      SC 13G/A - biote Corp. (0001819253) (Subject)

      11/12/24 4:15:18 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 5:17:02 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 2:11:05 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care